A phase I/II study evaluating potential pharmacokinetic (PK) drug-drug interactions (DDI) related to the association of oral palbociclib in combination with vemurafenib in patients with metastatic melanoma
Latest Information Update: 10 Apr 2019
At a glance
- Drugs Palbociclib (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Pharmacodynamics; Pharmacokinetics
Most Recent Events
- 10 Apr 2019 New trial record
- 03 Apr 2019 Results presented at the 110th Annual Meeting of the American Association for Cancer Research